It can be very difficult to find companies that are both flying under the radar, and still might have potential for gains. Many times, stocks are off investors’ radar screens for a reason, though there are some hidden gems that could be worth uncovering by those with a high risk tolerance.
One way to find these underappreciated stocks is by looking at companies that haven’t seen their share prices move higher lately, but have observed analysts raising earnings estimates for their stock. This trend could signal that investors haven’t quite embraced the rising estimate story yet, but that the potential for a big move higher is definitely there.
One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is Vical Incorporated (VICL). This Biotech stock has actually seen loss estimates narrowing from a loss of 32 cents to a loss of 22 cents now over the past month for the current fiscal year. But that is not yet reflected in its price, as the stock gained only 1.4% over the same time frame.
You should not be concerned about the price remaining muted going forward. This year’s expected earnings growth over the prior year is 40.3%, which should ultimately translate into price appreciation.
And if this isn’t enough, VICL currently carries a Zacks Rank #2 (Buy) which further underscores the potential for its outperformance (See the performance of Zacks' portfolios and strategies here: About Zacks Performance).
So if you are looking for a stock flying under-the-radar that is well-equipped to bounce down the road, make sure to consider Vical. Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for VICL and that now might be an interesting buying opportunity.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>